The EMSR offers full-service colony management. The EMSR can perform these services for all of your mouse colony needs:
- Identification and Genotype Services (including backcrossing onto a new genetic background)
- Timed Pregnancy Matings/Subsequent Plug Checking
Mice are generally dual identified by ear notching and ear tagging at the time of weaning. A tail tip is also collected at this time for genotyping analysis. Records will be maintained at the EMSR and provided to the investigator in monthly updates. Mice will be put on study at the appropriate age for the experimental design; the EMSR will take care of any paperwork to transfer the mice.
The following mouse models are available:
Model name: B6.129S4-Trp53tm2Tyj/Nci
Genetic model type: Conditional knockout
This strain has loxP sites inserted in into intron 1 and intron 10 of the p53 gene locus. The strain was obtained from NCI Frederick Mouse Repository (Info)
Model name:C57BL6/J CDX2-Cre mice.
Genetic model type:Transgenic.
CDX2-Cre mice express a 9.5 kb human caudal type homeo box 2 (CDX2) promoter/enhancer sequence directing expression of a nuclear-localized Cre recombinase predominantly to colonic epithelium during late gestation and in adult tissues. Specifically, Cre recombinase expression is observed in epithelium from the distal ileum and cecum, and throughout the colon from the crypt base to the luminal surface. Cre recombinase expression is also observed throughout the caudal region of the embryo during early development. The strain was obtained from Jackson laboratory (www.jax.org, stock #009350).
Model Name:B6.129 Kras
Genetic Model Type: Knock in
These mice carry a latent point-mutant allele of oncogenic K-ras2 (K-rasG12D). Cre-mediated recombination leads to deletion of a transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic protein. By crossing to a tissue-specific cre, you can generate any tissue lung specific model, including lung models (Promoter) and pancreas model (P48-cre). The lung model was established in the Jacks lab (ref.) in 2001, and the pancreas model was published in the Tuveson lab (ref.) in 2003. It is a useful GEM model that allows one to characterize stages of ras-dependent tumor progression.
Model Name:B6.FVB-Tg(Ipf1-cre)1Tuv (pdx-cre)
Genetic Model Type: Transgenic
Cre recombinase induces the release of genes that are floxed. Pdx-1-Cre mice exhibit a stochastic pattern of high-level Cre expression in the pancreas (Hingorani et al., 2003). When combined with Tyler Jacks' latent activatable K-ras allele, LSL-KrasG12D (Kras2, MMHCC strain code 01XJ6), Pdx-1-Cre causes ductal lesions that recapitulate the full spectrum of human pancreatic intraepithelial neoplasias (PanINs). Some of these lesions progress to invasive and metastatic adenocarcinomas. These mice are currently on a B6.FVB background and are being backcrossed further onto the B6 background. (Info)
Model Name:Villin-cre ER T2
Genetic Model Type: Transgenic
The Vil-cre is inducible with tamoxifen, usually administered IP for five consecutive days at a concentration of 10 mg/ml. The cre is normally induced at 5 weeks of age, with or without a booster when the mice are older. These mice are maintained on a Bl6 background.
Genetic Model Type: Transgenic Triple Mutant
These triple mutant mice carry the pdx-cre and B6.129 Kras mutations described above, along with a luciferase mutation that allows for bioluminescent imaging of pancreatic lesions with the administration of luciferin. Triple mutant mice start showing lesions at 20 weeks of age. They are maintained on a mixed Bl6.129 background.
Colonies are kept in maintenance mode and require several weeks lead time to increase production for experimental availability.
Disclaimer: The Experimental Mouse Shared Resource will perform experiments outlined in the investigator approved experimental designs with the highest care and quality. The Experimental Mouse Shared Resource is not responsible or liable for any claims, loss or damage arising from the quality of the material (cell lines etc.) or the experimental design (drug doses, frequency, etc.) provided by the Investigator.